New hope for tough pancreatic cancers: testing a targeted drug duo
NCT ID NCT06790602
Summary
This study is testing whether adding an immunotherapy drug (cemiplimab) to a standard chemotherapy (gemcitabine) can help people with advanced pancreatic cancer that has a specific genetic change (SWI/SNF alteration) and has worsened after their first treatment. The goal is to see if this combination can help patients live longer and better control the cancer compared to past treatments. It is for adults whose cancer has spread and who meet specific health criteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Diego
RECRUITINGLa Jolla, California, 92093, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.